Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up

Haematologica

Volumn 93, Issue 12, 2008, Pages 1792-1796

  Palandri, Francesca ^a   Castagnetti, Fausto ^a   Testoni, Nicoletta ^a   Luatti, Simona ^a   Marzocchi, Giulia ^a   Bassi, Simona ^b   Breccia, Massimo ^c   Alimena, Giuliana ^c   Pungolino, Ester ^d   Rege Cambrin, Giovanna ^e   Varaldo, Riccardo ^f   Miglino, Maurizio ^f   Specchia, Giorgina ^g   Zuffa, Eliana ^h   Ferrara, Felicetto ⁱ   Bocchia, Monica ^j   Saglio, Giuseppe ^e   Pane, Fabrizio ^k   Alberti, Daniele ^l   Martinelli, Giovanni ^a   Baccarani, Michele ^a   Rosti, Gianantonio ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Division of Hematology   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g Division of Hematology   (Italy)

^h Division of Hematology   (Italy)

ⁱ Division of Hematology   (Italy)

^j UNIVERSITY OF PERUGIA   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Blast crisis; Chronic myeloid leukemia; Imatinib; Long term; Outcome

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HYDROXYUREA; IMATINIB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BASOPHIL; BLAST CELL CRISIS; BONE MARROW; BONE MARROW CELL; BRAIN HEMORRHAGE; CHROMOSOME BANDING PATTERN; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG SAFETY; EDEMA; EXTRAMEDULLARY HEMATOPOIESIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE DIFFERENTIAL COUNT; LIVER DYSFUNCTION; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROMYELOCYTE; RASH; REMISSION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57349124075     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13068     Document Type: Article

References (21)

1. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999;86:2632-41.
2. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993;94:69-74.
3. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
5. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
6. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
7. Kaplan EL, P M. Nonparametric estimation from incomplete observations J Am Stat Assoc 1958;53:457-81.
8. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
9. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
10. Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003;88:1213-20.
11. Silver RT, Talpaz M, Sawyers CL. Four years of follow-up of 1027 patients with late chronic phase (LCP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004; 104:11[Abstract 23].
12. Paschka P, Muller MC, Merx K, Kreil S, Schoch C, Lahaye T, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-94.
13. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-9.
14. Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007;109:1543-9.
15. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 2007;48:283-9.
16. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007;109:899-906.
17. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-55.
18. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9.
19. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6.
20. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-13.
21. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.